In this issue:
Diagnostic likelihood thresholds for a working diagnosis of IPF
Diagnostic accuracy of TBLC for ILD diagnosis
Comparison of visual features on CT for determining IPF outcome
Pamrevlumab for IPF
Nintedanib for progressive fibrosing ILD: subgroup analyses
Expectations, experiences and satisfaction with nintedanib + pirfenidone in IPF
Nintedanib and sildenafil in IPF and right heart dysfunction
Opportunities to diagnose fibrotic lung diseases in routine care
Artificial vs. natural stoneassociated silicosis
Income and other contributors to poor sarcoidosis outcomes
Please login below to download this issue (PDF)